SCPH Stock Summary and Trading Ideas (Scpharmaceuticals | NASDAQ:SCPH)

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Scpharmaceuticals trades on the NASDAQ stock market under the symbol SCPH.

As of May 17, 2024, SCPH stock price declined to $4.75 with 231,534 million shares trading.

SCPH has a beta of 0.64, meaning it tends to be less sensitive to market movements. SCPH has a correlation of 0.03 to the broad based SPY ETF.

SCPH has a market cap of $171.26 million. This is considered a Micro Cap stock.

Last quarter Scpharmaceuticals reported $6 million in Revenue and -$.36 earnings per share. This beat revenue expectation by $122,000 and exceeded earnings estimates by $.08.

In the last 3 years, SCPH stock traded as high as $12.75 and as low as $3.48.

The top ETF exchange traded funds that SCPH belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

SCPH has underperformed the market in the last year with a price return of -57.9% while the SPY ETF gained +29.1%. SCPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.2% and +1.9%, respectively, while the SPY returned +6.3% and +3.6%, respectively.

SCPH support price is $4.62 and resistance is $5.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCPH stock will trade within this expected range on the day.